rosiglitazone has been researched along with pyrazines in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bergman, AJ; Cilissen, C; Davies, MJ; Gottesdiener, KM; Haazen, W; Herman, GA; Luo, WL; Mistry, GC; Wagner, JA | 1 |
| Eisendle, K; Fritsch, P; Linder, D; Philipp, W; Piza, H; Ratzinger, G; Schmuth, M; Zelger, B | 1 |
| Davies, MJ; Engel, SS; Loeys, T; Scott, R | 1 |
| Alemao, E; Chen, J; Cook, J; Gouveia, M; Jameson, K; Krishnarajah, G; Nocea, G; Schwarz, B; Sintonen, H; Yin, D | 1 |
| Gallen, IW; Lumb, AN | 1 |
| Alexander, CM; Chapell, R; Gould, AL | 1 |
| Nauck, MA | 1 |
| Amatruda, JM; Aschner, P; Chen, Y; Dobs, AS; Duran, L; Ferreira, JC; Goldstein, BJ; Golm, GT; Hill, JS; Horton, ES; Kaufman, KD; Langdon, RB; Umpierrez, GE; Williams-Herman, DE | 1 |
| Colette, C; Comenducci, A; Dejager, S; Monnier, L; Vallée, D | 1 |
| Cander, S; Cinkilic, N; Ersoy, C; Gul, CB; Oz Gul, O; Tuncel, E; Vatan, O; Yılmaz, D | 1 |
| Borders-Hemphill, V; Hampp, C; Moeny, DG; Wysowski, DK | 1 |
| He, L; Lee, J; Mendell-Harary, J; Tao, B; Walker, J; Wickremasingha, P; Wight, D | 1 |
| Altamirano-Lagos, MJ; Fernández-Fierro, A; Funes, SC; Gómez-Santander, F; Jara, EL; Kalergis, AM; Mackern-Oberti, JP; Pulgar-Sepúlveda, R; Rebolledo-Zelada, D; Ríos, M; Rivera-Perez, D; Roa, JC; Villarroel, A | 1 |
2 review(s) available for rosiglitazone and pyrazines
| Article | Year |
|---|---|
Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone.
Topics: Bayes Theorem; Confidence Intervals; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Pioglitazone; Pyrazines; Randomized Controlled Trials as Topic; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles | 2009 |
The design of the liraglutide clinical trial programme.
Topics: Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2012 |
4 trial(s) available for rosiglitazone and pyrazines
| Article | Year |
|---|---|
Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects.
Topics: Adenosine Deaminase Inhibitors; Adult; Cross-Over Studies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glycoproteins; Humans; Hypoglycemic Agents; Male; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2007 |
Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes.
Topics: Analysis of Variance; Biomarkers; Blood Glucose; Body Weight; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Triglycerides | 2008 |
Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes.
Topics: Adult; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2013 |
Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose?
Topics: Adamantane; Adult; Aged; Analysis of Variance; Area Under Curve; Basal Metabolism; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrazines; Pyrrolidines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Vildagliptin | 2012 |
7 other study(ies) available for rosiglitazone and pyrazines
| Article | Year |
|---|---|
Inflammation and lipid accumulation in xanthoma disseminatum: Therapeutic considerations.
Topics: Adult; Histiocytosis, Non-Langerhans-Cell; Humans; Inflammation; Lipid Metabolism; Male; Pyrazines; Rosiglitazone; Simvastatin; Thiazolidinediones | 2008 |
Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Europe; Female; Glycated Hemoglobin; Health Care Costs; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Biological; Models, Economic; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles | 2008 |
Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin(1).
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Hepatocyte Nuclear Factor 1-alpha; Humans; Hypoglycemic Agents; Middle Aged; Pioglitazone; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2009 |
Comparative genotoxic and cytotoxic effects of the oral antidiabetic drugs sitagliptin, rosiglitazone, and pioglitazone in patients with type-2 diabetes: a cross-sectional, observational pilot study.
Topics: Aged; Blood Glucose; Chromosome Aberrations; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Micronuclei, Chromosome-Defective; Middle Aged; Pilot Projects; Pioglitazone; Pyrazines; Rosiglitazone; Sister Chromatid Exchange; Sitagliptin Phosphate; Thiazolidinediones; Triazoles | 2013 |
Use of antidiabetic drugs in the U.S., 2003-2012.
Topics: Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Prescriptions; Drug Therapy, Combination; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Marketing of Health Services; Metformin; Pharmacies; Prescription Drugs; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; United States | 2014 |
Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin.
Topics: Adolescent; Adult; Allylamine; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Anticonvulsants; Antihypertensive Agents; Area Under Curve; Aspirin; Atenolol; Colesevelam Hydrochloride; Dose-Response Relationship, Drug; Drug Interactions; Enalapril; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Phenytoin; Pyrazines; Rosiglitazone; Sitagliptin Phosphate; Thiazolidinediones; Tissue Distribution; Triazoles; Young Adult | 2014 |
Tolerogenic dendritic cell transfer ameliorates systemic lupus erythematosus in mice.
Topics: Animals; Antibodies, Antinuclear; Cell Differentiation; Cells, Cultured; Dendritic Cells; Dexamethasone; Disease Models, Animal; Humans; Immune Tolerance; Immunotherapy, Adoptive; Kidney; Lupus Erythematosus, Systemic; Lymphocyte Activation; Mice; Mice, Inbred MRL lpr; Pyrazines; Pyrroles; Rosiglitazone; T-Lymphocytes, Regulatory | 2019 |